CoChat

A Double-Blind, Randomized, Placebo-Controlled Trial of Augmentation With Lamotrigine or Placebo in Patients Concomitantly Treated With Fluoxetine for Resistant Major Depressive Episodes

Barbosa, Laura, Berk, Michael, Vorster, Merryll · 2003 · The Journal of Clinical Psychiatry

The DOI matches its Crossref record.

Abstract

BACKGROUND: Evidence of the antidepressant efficacy of lamotrigine is increasing, although there are no placebo-controlled trials of lamotrigine augmentation in depression. The aim of this study was to assess if augmentation with lamotrigine was superior to placebo in patients who were receiving fluoxetine for resistant major depressive episodes. METHOD: Twenty-three patients who had experienced at least 1 major depressive episode that was resistant to at least 1 prior trial of antidepressant therapy were selected. These patients were treated with fluoxetine, 20 mg/day, and concomitantly randomly assigned to receive either lamotrigine (N = 13) or placebo (N = 10) for 6 weeks. The dose of lamotrigine was titrated upward from 25 mg/day to 100 mg/day. Patients suffering from bipolar II disorder (N = 8) or from major depressive disorder (N = 15) (DSM-IV criteria) were enrolled, resulting in heterogeneity of the sample. The primary outcome measure was Hamilton Rating Scale for Depression score. Data were collected from 2000-2001. RESULTS: Lamotrigine was statistically superior to placebo on the Clinical Global Impressions scale at endpoint, both in absolute terms (mean +/- SD Clinical Global Impressions-Severity of Illness scores: lamotrigine, 2.15 +/- 1.28; placebo, 3.40 +/- 1.17; p =.0308) and using a responder analysis, with response defined as a Clinical Global Impressions-Improvement score of 2 or less (lamotrigine, 84.62% [N = 11]; placebo, 30.00% [N = 3]; p =.013). The effect of lamotrigine on Clinical Global Impressions scale scores was seen in both major depressive disorder and bipolar II disorder. Lamotrigine, however, failed to separate statistically from placebo on the Hamilton Rating Scale for Depression and Montgomery-Asberg Depression Rating Scale. This failure to differentiate on a primary outcome measure is essentially a negative study result. This result is most likely an artifact of the small sample size used and the resultant limited power of the study. CONCLUSION: The results of this trial add to the literature suggesting potential efficacy of the antidepressant profile of lamotrigine. In addition, this study points to a possible role of lamotrigine as an augmentation agent in depression.

Overview

Integrity signals

Registry

Crossref · 10.4088/jcp.v64n0407

Cites

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Still being checked.

Cited by

See all 165

Metadata

Authors
Barbosa, L., Berk, M., & Vorster, M.
Affiliations
University of the Witwatersrand (ZA)
Venue
The Journal of Clinical Psychiatry
Published
2003-04-15
Volume
64
Issue
4
Pages
403-407
ISSN
0160-6689 (ISSN-L)
OpenAlex
W2064478935
Cited by
165
References
0
Citations by year
2025: 3 · 2024: 4 · 2023: 1 · 2022: 1 · 2021: 4 · 2020: 5 · 2019: 2 · 2018: 2 · 2017: 4 · 2016: 6 · 2015: 9 · 2014: 11 · 2013: 6 · 2012: 11
FWCI
9.00
Type
journal article
Language
en
Open access
closed
Locations
  • The Journal of Clinical Psychiatry (publishedVersion)
  • PubMed (publishedVersion)
  • Deakin Research Online (Deakin University) (submittedVersion)
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
  • Health Sciences › Medicine › Psychiatry and Mental health › Bipolar Disorder and Treatment
  • Social Sciences › Psychology › Clinical Psychology › Psychological Treatments and Disorders
Keywords
lamotrigine, fluoxetine, antidepressant augmentation, treatment-resistant depression, major depressive disorder, bipolar II disorder, antidepressant efficacy, Clinical Global Impression Scale, Hamilton Depression Rating Scale, Montgomery-Asberg Depression Rating Scale, small sample size limitations, responder analysis, dose titration, adverse events, drug discontinuation
MeSH terms
Lamotrigine, Adolescent, Adult, Aged, Anticonvulsants, Depressive Disorder, Double-Blind Method, Drug Administration Schedule, Drug Therapy, Combination, Female, Fluoxetine, Humans, Male, Middle Aged, Pilot Projects, Psychiatric Status Rating Scales, Research Design, Severity of Illness Index, Triazines, Placebo Effect, Treatment Outcome, Outcome Assessment, Health Care, Selective Serotonin Reuptake Inhibitors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A Double-Blind, Randomized, Placebo-Controlled Trial of Augmentation With Lamotrigine or Placebo in Patients Concomitantly Treated With Fluoxetine for Resistant Major Depressive Episodes. https://app.cochat.ai/papers/10.4088/jcp.v64n0407
The paper
Barbosa, L., Berk, M., & Vorster, M. (2003). A Double-Blind, Randomized, Placebo-Controlled Trial of Augmentation With Lamotrigine or Placebo in Patients Concomitantly Treated With Fluoxetine for Resistant Major Depressive Episodes. The Journal of Clinical Psychiatry. https://doi.org/10.4088/jcp.v64n0407

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.